Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA
Published in Diabetes Care
Key Findings
Oral alpha-lipoic acid 600 mg/day for 5 weeks reduced Total Symptom Score by 51% versus 32% for placebo; higher doses added side effects without added benefit.
Conclusions
600 mg/day oral alpha-lipoic acid improves neuropathic symptoms with a favourable risk-benefit ratio.
Limitations
Five-week duration; subjective symptom scores; no hard nerve-function endpoints.
Supplements Studied
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
Outcomes Measured
Oral alpha-lipoic acid 600 mg/day reduced Total Symptom Score by 51% versus 32% for placebo.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.